Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

Cassava Sciences IncTrade
BlackRock TCP Capital CorpTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs BlackRock TCP Capital Corp — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: BlackRock TCP Capital Corp is far larger — about 6.9× Cassava Sciences Inc's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNATCPC
Market Cap
$47.75M$327.64M
Sector
HealthFinancials
52-Week High
$4.64$7.26
52-Week Low
$0.87$3.13
Enterprise Value
-$34.93M
Dividend Yield
19.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

BlackRock TCP Capital Corp

TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.

The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About BlackRock TCP Capital Corp

BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.

Read more on TCPC